Last reviewed · How we verify
IR Tablet under Fasted conditions
At a glance
| Generic name | IR Tablet under Fasted conditions |
|---|---|
| Also known as | Codeine Phosphate/Guaifenesin 20mg/400mg |
| Sponsor | Nexgen Pharma, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults (PHASE1)
- Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects (PHASE1)
- A Study of Selexipag in Healthy Male Participant (PHASE1)
- A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants (PHASE1)
- A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants (PHASE1)
- A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults (PHASE1)
- A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants (PHASE1)
- A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IR Tablet under Fasted conditions CI brief — competitive landscape report
- IR Tablet under Fasted conditions updates RSS · CI watch RSS
- Nexgen Pharma, Inc portfolio CI